Description

BML-277 (Chk2 Inhibitor II) is an arylbenzimidazole inhibitor of checkpoint kinase (CHK) 2. This compound displays cytoprotective activity, protecting CD4+ and CD8+ T cells against radiation-induced apoptosis.